NDAORALCAPSULE
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
COXANTO (oxaprozin) by Teva is cyclooxygenase inhibitors [moa]. First approved in 2023.
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COXANTO (oxaprozin) is an oral nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase enzymes to reduce inflammation and pain. Approved by FDA in October 2023, it is a small-molecule capsule indicated for inflammatory and pain conditions. The product is currently in growth lifecycle stage as a recent NDA approval from Teva.
Growth
As a recently approved NSAID in growth phase, the brand team is likely expanding with field force, medical science liaisons, and commercial strategy roles to capture market share against established competitors.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Drug-drug Interaction Study of FYU-981 and Oxaprozin
Started Nov 2017
12 enrolled
Healthy
Career Relevance
COXANTO represents a growth-stage commercial opportunity for pharma professionals seeking roles in brand establishment and market capture within the competitive NSAID space. Career growth will depend on the brand's ability to differentiate in a crowded market and achieve payer coverage in a cost-sensitive category.
Brand Manager
Worked on COXANTO at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.